RGD DISEASE ONTOLOGY - ANNOTATIONS
RGD uses the Human Disease Ontology (DO, https://disease-ontology.org/) for disease curation across species. RGD automatically downloads each new release of the ontology on a monthly basis. Some additional terms which are required for RGD's curation purposes but are not currently covered in the official version of DO have been added. As corresponding terms are added to DO, these custom terms are retired and the DO terms substituted in existing annotations and subsequently used for curation.
Term: Anorexia
Accession: DOID:9001109
browse the term
Definition: The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.
Synonyms: exact_synonym: Anorexias
primary_id: MESH:D000855
G
Abat
4-aminobutyrate aminotransferase
IMP
RGD
PMID:6534893
RGD:10047083
NCBI chr10:7,503,351...7,599,474
Ensembl chr10:7,492,022...7,599,474
G
Cck
cholecystokinin
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:22903826 PMID:24385417
NCBI chr 8:130,031,012...130,037,702
Ensembl chr 8:130,031,013...130,037,686
G
Crh
corticotropin releasing hormone
induces
IDA ISO
CTD Direct Evidence: marker/mechanism
CTD RGD
PMID:16420149 PMID:12429558 PMID:11981590
RGD:704394 , RGD:9835031
NCBI chr 2:104,059,184...104,061,048
Ensembl chr 2:104,058,770...104,061,386
G
Crhr1
corticotropin releasing hormone receptor 1
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:16420149
NCBI chr10:89,540,192...89,583,466
Ensembl chr10:89,540,192...89,583,466
G
Crhr2
corticotropin releasing hormone receptor 2
IDA ISO
CTD Direct Evidence: marker/mechanism
CTD RGD
PMID:17627984 PMID:17050037
RGD:5131264
NCBI chr 4:85,553,163...85,596,203
Ensembl chr 4:85,554,268...85,596,318
G
Dbh
dopamine beta-hydroxylase
IMP
RGD
PMID:20554938
RGD:5129235
NCBI chr 3:30,886,313...30,903,313
Ensembl chr 3:30,886,328...30,903,316
G
Gcg
glucagon
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:21824258 PMID:28633506
NCBI chr 3:67,522,489...67,531,533
Ensembl chr 3:67,522,489...67,531,533
G
Ghrl
ghrelin and obestatin prepropeptide
ISO
RGD
PMID:15788704
RGD:1642818
NCBI chr 4:148,421,315...148,431,128
Ensembl chr 4:148,421,315...148,425,969
G
Gip
gastric inhibitory polypeptide
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:28633506 PMID:28666375 PMID:29689362
NCBI chr10:81,465,070...81,473,216
Ensembl chr10:81,465,062...81,473,216
G
Gpx1
glutathione peroxidase 1
treatment
ISO
associated with Uremia
RGD
PMID:12005352
RGD:11352773
NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581
G
Htr1b
5-hydroxytryptamine receptor 1B
IEP
associated with Sarcoma;protein:increased expression:hypothalamus
RGD
PMID:15698923
RGD:1626473
NCBI chr 8:91,395,405...91,414,815
Ensembl chr 8:91,052,432...91,418,583
G
Htr4
5-hydroxytryptamine receptor 4
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:15146954
NCBI chr18:58,036,277...58,221,327
Ensembl chr18:58,036,277...58,219,622
G
Il1a
interleukin 1 alpha
IEP
associated with Sarcoma, Experimental;protein:increased expression:cerebrospinal fluid
RGD
PMID:8748250
RGD:7794755
NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013
G
Il1b
interleukin 1 beta
IEP ISO
mRNA:increased expression:hypothalamus CTD Direct Evidence: marker/mechanism
CTD RGD
PMID:12077204 PMID:25392278 PMID:22902858
RGD:13825124
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
G
Il1rn
interleukin 1 receptor antagonist
IEP ISO
associated with Adenocarcinoma;mRNA:increased expression:cerebral cortex, hypothalamus (rat) CTD Direct Evidence: therapeutic
CTD RGD
PMID:25392278 PMID:9688694
RGD:8551744
NCBI chr 3:27,509,836...27,525,738
Ensembl chr 3:27,509,798...27,525,732
G
Il2
interleukin 2
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:8635092
NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672
G
Npsr1
neuropeptide S receptor 1
IMP
RGD
PMID:19821837
RGD:9835045
NCBI chr 8:30,882,830...31,107,425
Ensembl chr 8:30,882,830...31,107,425
G
Npy
neuropeptide Y
IEP ISO
associated with Neoplasms CTD Direct Evidence: marker/mechanism
CTD RGD
PMID:16084549 PMID:16101753 PMID:25825358 PMID:17234300
RGD:10448965
NCBI chr 4:80,212,111...80,219,310
Ensembl chr 4:80,212,111...80,219,310
G
Npy1r
neuropeptide Y receptor Y1
IEP
associated with Neoplasms;mRNA, protein:decreased expression:hypothalamus
RGD
PMID:17234300
RGD:10448965
NCBI chr16:27,804,416...27,814,070
Ensembl chr16:27,804,416...27,813,387
G
Oprl1
opioid related nociceptin receptor 1
treatment
IDA
RGD
PMID:11981590
RGD:9835031
NCBI chr 3:189,209,495...189,225,406
Ensembl chr 3:189,212,175...189,217,426
G
Ptgs2
prostaglandin-endoperoxide synthase 2
treatment
IMP
RGD
PMID:22902858
RGD:13825124
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
G
Pyy
peptide YY
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:22903826 PMID:29689362
NCBI chr10:87,561,347...87,562,470
Ensembl chr10:87,561,353...87,562,206
G
Tac1
tachykinin, precursor 1
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:30336258
NCBI chr 4:36,645,344...36,653,548
Ensembl chr 4:36,645,571...36,653,546
G
Tnf
tumor necrosis factor
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:25392278
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
G
Tnfrsf10b
TNF receptor superfamily member 10b
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:19652058
NCBI chr15:51,249,883...51,278,091
Ensembl chr15:51,250,112...51,278,082
G
Tnfrsf1a
TNF receptor superfamily member 1A
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:18801959
NCBI chr 4:159,837,119...159,849,817
Ensembl chr 4:159,837,032...159,849,816
G
Ucn2
urocortin 2
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:17627984
NCBI chr 8:118,516,111...118,517,660
Ensembl chr 8:118,483,364...118,517,439
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all